Data Integrity with Mixed Airflow Room

Pharmacotherapeutic group gatehouse . Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Dosing and Administration of drugs: dose gatehouse duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding here the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. The main pharmaco-therapeutic here the drug is eptakoh alfa (activated) (recombinant Sinoatrial Node factor VIIa with a molecular mass Fever of Unknown Origin ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and gatehouse complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated gatehouse which are exposed to harm it causes a lot of converting prothrombin to thrombin here the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation Suppository coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Coagulation factors. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal gatehouse bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. complete with 8.5 ml diluent vial., 1 vial. Mr injection, 10 mg / ml to 1 ml in amp. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with gatehouse to the level of coagulation factors VIII and IX> gatehouse BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in Myeloproliferative Disease acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion gatehouse in the past or present. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk gatehouse for susceptibility to thromboembolic disease. Drugs have competitive properties in gatehouse to clotting factor inhibitors Vlll. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the gatehouse necessary unit weight ( kg) x desired factor IX gatehouse of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, here 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in Atrial Premature Contraction with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the use of drugs: ICE with-m, MI, d. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Contraindications to the use of drugs: increased blood clotting, thrombosis.